| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Northern Ireland Neurology Service (Dr. McDonnell), Royal Victoria Hospital Hospital, and the Department of Medicine (Dr. Hawkins), Queen's University, Belfast, Northern Ireland.
Address correspondence and reprint requests to Dr Hawkins, Northern Ireland Neurology Service, Quin House, Royal Victoria Hospital, Grosvenor Road, Belfast, Northern Ireland BT12 6BA.
We wanted to establish the point prevalence of MS in Northern Ireland. Northern Ireland has been a known high-risk area for MS since the original work of Allison and Millar in 1951. Studies demonstrated a rising prevalence in 1951 of 41 (95% CI, 37 to 441, in 1961 of 57 (95% CI, 53 to 611, and in 1986 of 104 (95% CI, 85 to 128)/105 population for probable/early probable and latent disease. We surveyed four districts (area 2,030 km2, population 151,000). Case sources included Regional Neurology Service records, postal survey of general medical practitioners, hospital databases, MS charities, and MS respite facilities. We used the Poser and Allison and Millar criteria in diagnosis. From a provisional list of 402 patients, 254 (177 female, 77 male, ratio 2.3:l) were identified with definite or probable disease by the Poser criteria, prevalence 168.2/105 (95% CI, 147.5 to 188.9/105) with 34 suspected patients and an overall prevalence 190.7/105 (95% CI, 168.7 to 212.7/105). We interviewed and examined over 87% of these 288 patients. There were 246 patients classified as probable/early probable and latent by Allison and Millar, prevalence 162.9/105 (95% CI, 142.6 to 183.3/105). Seventy-six probable or definite patients had onset between 1985 and 1992 (estimated incidence, 6.5/105/yr). Age range of prevalent patients was 18 to 79 years (mean ± SD, 49.2 ± 13.3 years). Mean age at onset was 31.6 ± 10.1 years. Overall, 12.5% had primary progressive disease and 20% had benign MS. Northern Ireland has an extremely high and rising MS prevalence. This may reflect a true increase in disease incidence or may be explained by increasing survival, improved case ascertainment, increased disease awareness, or improved laboratory and radiologic diagnosis.
Received June 3, 1997. Accepted in final form August 13, 1997.
This article has been cited by other articles:
|
|
 |
|
  C Hirst, G Ingram, T Pickersgill, R Swingler, D A S Compston, and N P Robertson Increasing prevalence and incidence of multiple sclerosis in South East Wales J. Neurol. Neurosurg. Psychiatry, April 1, 2009; 80(4): 386 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Gray, G. McDonnell, and S. Hawkins Factors in the rising prevalence of multiple sclerosis in the north-east of Ireland Multiple Sclerosis, August 1, 2008; 14(7): 880 - 886. [Abstract] [PDF]
|
|
|
|
|
|
E. Granieri, C. Monaldini, R. De Gennaro, S. Guttmann, M. Volpini, M. Stumpo, P. Fazio, and I. Casetta Multiple sclerosis in the Republic of San Marino: a prevalence and incidence study Multiple Sclerosis, April 1, 2008; 14(3): 325 - 329. [Abstract] [PDF]
|
|
|
|
|
|
J. Sweetland, A. Riazi, S.J. Cano, and E.D. Playford Vocational rehabilitation services for people with multiple sclerosis: what patients want from clinicians and employers Multiple Sclerosis, November 1, 2007; 13(9): 1183 - 1189. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Tintore, A. Rovira, J. Rio, C. Nos, E. Grive, N. Tellez, R. Pelayo, M. Comabella, J. Sastre-Garriga, and X. Montalban Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology, September 26, 2006; 67(6): 968 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Stuve, M. Kita, D. Pelletier, R. J Fox, J. Stone, D. E Goodkin, and S. S Zamvil Mitoxantrone as a potential therapy for primary progressive multiple sclerosis Multiple Sclerosis, June 1, 2004; 10(1_suppl): S58 - S61. [Abstract] [PDF]
|
|
|
|
|
|
O. Stuve, M. Kita, D. Pelletier, R. J Fox, J. Stone, D. E Goodkin, and S. S Zamvil Mitoxantrone as a potential therapy for primary progressive multiple sclerosis Multiple Sclerosis, May 1, 2004; 10(3_suppl): S58 - S61. [Abstract] [PDF]
|
|
|
|
|
|
C McGuigan, A McCarthy, C Quigley, L Bannan, S A Hawkins, and M Hutchinson Latitudinal variation in the prevalence of multiple sclerosis in Ireland, an effect of genetic diversity J. Neurol. Neurosurg. Psychiatry, April 1, 2004; 75(4): 572 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J A Silversides, S V Heggarty, G V McDonnell, S A Hawkins, and C A Graham Influence of C C R5 {delta}32 polymorphism on multiple sclerosis susceptibility and disease course Multiple Sclerosis, April 1, 2004; 10(2): 149 - 152. [Abstract] [PDF]
|
|
|
|
|
|
C M Fox, S Bensa, I Bray, and J P Zajicek The epidemiology of multiple sclerosis in Devon: a comparison of the new and old classification criteria J. Neurol. Neurosurg. Psychiatry, January 1, 2004; 75(1): 56 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Ranzato, P Perini, E Tzintzeva, M Tiberio, M Calabrese, M Ermani, F Davetag, L De Zanche, E Garbin, F Verdelli, et al. Increasing frequency of multiple sclerosis in Padova, Italy: a 30 year epidemiological survey Multiple Sclerosis, August 1, 2003; 9(4): 387 - 392. [Abstract] [PDF]
|
|
|
|
|
|
H. Kalanie, K. Gharagozli, and A. R. Kalanie Multiple sclerosis: report on 200 cases from Iran Multiple Sclerosis, February 1, 2003; 9(1): 36 - 38. [Abstract] [PDF]
|
|
|
|
|
|
G V McDonnell and S A Hawkins An assessment of the spectrum of disability and handicap in multiple sclerosis: a population-based study Multiple Sclerosis, April 1, 2001; 7(2): 111 - 117. [Abstract] [PDF]
|
|
|
|
 |
|
 B. K. MacDonald, O. C. Cockerell, J. W. A. S. Sander, and S. D. Shorvon The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK Brain, April 1, 2000; 123(4): 665 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Totaro, C. Marini, A. Cialfi, M. Giunta, and A. Carolei Prevalence of multiple sclerosis in the L'Aquila district, central Italy J. Neurol. Neurosurg. Psychiatry, March 1, 2000; 68(3): 349 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. Feigin, S. V. Shishkin, G. M. Tzirkin, T. E. Vinogradova, A. V. Tarasov, S. P. Vinogradov, and Y. P. Nikitin A Population-Based Study of Transient Ischemic Attack Incidence in Novosibirsk, Russia, 1987-1988 and 1996-1997 Stroke, January 1, 2000; 31(1): 9 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Hernan, M. J. Olek, and A. Ascherio Geographic variation of MS incidence in two prospective studies of US women Neurology, November 1, 1999; 53(8): 1711 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. V. McDonnell, S. A. Hawkins, and B. G. Weinshenker Major histocompatibility complex class II alleles and the course and outcome of MS Neurology, September 1, 1999; 53(4): 893 - 893. [Full Text] [PDF]
|
|
|
|
|
|
S A Hawkins and G V McDonnell Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors J. Neurol. Neurosurg. Psychiatry, August 1, 1999; 67(2): 148 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G V MCDONNELL, S A HAWKINS;, and P M ROTHWELL Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging analysis of 17 patients. J. Neurol. Neurosurg. Psychiatry, March 1, 1999; 66(3): 411 - 412. [Full Text]
|
|
|
|
|
|
R. B. Forbes, R. J. Swingler, S. A. Hawkins, and G. V. McDonnell An epidemiologic study of multiple sclerosis in Northern Ireland Neurology, January 1, 1999; 52(1): 214 - 214. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
